In May 2026, a formally published 197-patient case series documents Fenbendazole/Ivermectin/Mebendazole outcomes across 17 stage IV cancer types — including up to 99.7% tumor volume reduction in pancreatic cases. A Molecules study (May 2025) showed 100% mouse survival with Fenbendazole vs 0% untreated in cervical cancer, and for the first time confirmed it targets cancer stem cells. Frontiers in Pharmacology (July 2025) identified a completely new anticancer mechanism: pyropt